Quick answer: Retatrutide (LY3437943) is an investigational peptide studied for activity at three hormone receptors: GIP, GLP-1, and glucagon. It is not FDA-approved. Clinical-trial results and regulatory approval are separate steps.
This research-focused guide explains the name, receptor design, published clinical research, and FDA status. It does not provide directions for personal use, dosing, mixing, or sourcing.
What is retatrutide?
Retatrutide, also known by the development code LY3437943, is a single investigational peptide designed to activate receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Researchers describe it as a triple agonist because it is studied across three receptor targets.
“Reta” is an informal shortened search term. “GLP-3” also appears online, but it is not the name of a third GLP receptor or a formal scientific classification. The clearer description is a GIP, GLP-1, and glucagon receptor agonist.
What does “triple-receptor agonist” mean?
An agonist binds to and activates a receptor. Retatrutide’s design is being studied across three distinct receptor systems:
- GIP receptor: one incretin-related target included in the molecule’s design.
- GLP-1 receptor: a target involved in the body’s response to food and glucose regulation. MedlinePlus offers general GLP-1 agonist background; retatrutide itself remains investigational.
- Glucagon receptor: the third target in the triple-agonist design.
These labels describe receptor activity studied in research. They do not establish that a product is safe, effective, approved, or suitable for an individual.
What does clinical research show?
A randomized Phase 2 obesity trial was published in The New England Journal of Medicine in 2023. Phase 3 results were also reported in 2026, including the TRIUMPH-1 paper published in NEJM on September 29, 2026. Each trial studies defined participants and outcomes; findings in one group should not automatically be generalized to every population or condition.
When reading a study, check its phase, participant criteria, comparison group, duration, endpoints, and whether it is a peer-reviewed paper, trial-registry entry, or company announcement. A trial result is evidence about that study—not a guarantee for an individual and not regulatory approval.
What is retatrutide’s FDA status?
As of October 10, 2026, retatrutide is not FDA-approved. FDA states that retatrutide cannot be used in compounding under federal law and warns about products sold directly to consumers under labels such as “for research purposes” or “not for human consumption.” FDA says such products may have unknown quality and may be harmful.
Material sold online with a research-use label is not the same as investigational material, controls, and oversight used in a clinical trial. This article does not endorse buying or using retatrutide products. For regulatory updates, consult FDA and official clinical-trial records rather than seller claims or social-media posts.
Frequently asked questions
Is retatrutide the same as a GLP-1 drug?
Not exactly. Retatrutide is studied as a triple agonist targeting GIP, GLP-1, and glucagon receptors. Calling it only a “GLP-1” leaves out two targets.
Is “GLP-3” the official name for retatrutide?
No. “GLP-3” is an informal nickname found in some online descriptions. It is clearer to call retatrutide an investigational GIP, GLP-1, and glucagon receptor triple agonist.
Is retatrutide FDA-approved?
No. It remains investigational. FDA also warns against unapproved retatrutide products marketed to consumers.
Does a Phase 3 result mean the medicine is approved?
No. Clinical-trial findings and regulatory approval are separate steps. FDA evaluates an application before a medicine can be approved for a particular use.
References
- U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Accessed October 10, 2026.
- U.S. Food and Drug Administration. GenLabMeds Warning Letter. September 9, 2025.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial. New England Journal of Medicine. 2023;389:514–526. doi:10.1056/NEJMoa2301972.
- Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. Published September 29, 2026. TRIUMPH-1.
- MedlinePlus Medical Encyclopedia. GLP-1 agonists. Used for general GLP-1 context, not as a retatrutide monograph.
Related research guides
- What are research peptides? Laboratory use and documentation
- How to read a research peptide certificate of analysis
Editorial note: This article is for research education, not medical advice. Retatrutide is investigational and not FDA-approved. Information checked October 10, 2026.
